Mainstream

Viking Therapeutics outlines Phase III VANQUISH trial enrollment of 5,600 patients while advancing oral obesity program

Viking Therapeutics outlines Phase III VANQUISH trial enrollment of 5,600 patients while advancing oral obesity program

Post ContentvktxRead More

You might also be interested in reading Glamsterdam hits Ethereum’s Sepolia testnet on Oct 6. The L1 is scaling alongside rollups..

July 24, 2025
In Mainstream